PharmaResources (Shanghai) Future Growth
Future criteria checks 5/6
PharmaResources (Shanghai) is forecast to grow earnings and revenue by 76.8% and 42.4% per annum respectively while EPS is expected to grow by 77.4% per annum.
Key information
76.8%
Earnings growth rate
77.4%
EPS growth rate
Life Sciences earnings growth | 28.1% |
Revenue growth rate | 42.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 12 Sep 2023 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 1,119 | 195 | N/A | 162 | 1 |
12/31/2024 | 852 | 146 | N/A | 117 | 1 |
3/31/2024 | 499 | 26 | -180 | 17 | N/A |
12/31/2023 | 490 | 38 | -227 | 21 | N/A |
9/30/2023 | 514 | 75 | -154 | 81 | N/A |
6/30/2023 | 511 | 80 | -172 | 92 | N/A |
3/31/2023 | 496 | 72 | -99 | 85 | N/A |
1/1/2023 | 479 | 67 | -25 | 99 | N/A |
9/30/2022 | 485 | 72 | -5 | 122 | N/A |
6/30/2022 | 465 | 72 | 41 | 127 | N/A |
3/31/2022 | 458 | 73 | 36 | 122 | N/A |
1/1/2022 | 448 | 74 | 13 | 105 | N/A |
9/30/2021 | 377 | 48 | -1 | 66 | N/A |
12/31/2020 | 283 | 49 | 21 | 54 | N/A |
12/31/2019 | 245 | 47 | 7 | 41 | N/A |
6/30/2019 | 171 | 30 | 20 | 36 | N/A |
3/31/2019 | 149 | 19 | 13 | 27 | N/A |
12/31/2018 | 126 | 8 | 6 | 18 | N/A |
9/30/2018 | 127 | 10 | 4 | 20 | N/A |
6/30/2018 | 127 | 11 | 3 | 23 | N/A |
3/31/2018 | 131 | 16 | 5 | 26 | N/A |
12/31/2017 | 135 | 20 | N/A | 29 | N/A |
9/30/2017 | 131 | 20 | N/A | 26 | N/A |
6/30/2017 | 127 | 19 | N/A | 24 | N/A |
3/31/2017 | 117 | 16 | N/A | 23 | N/A |
12/31/2016 | 107 | 14 | N/A | 22 | N/A |
9/30/2016 | 95 | 11 | N/A | 13 | N/A |
6/30/2016 | 84 | 9 | N/A | 3 | N/A |
3/31/2016 | 80 | 7 | N/A | 1 | N/A |
1/1/2016 | 76 | 6 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 301230's forecast earnings growth (76.8% per year) is above the savings rate (2.9%).
Earnings vs Market: 301230's earnings (76.8% per year) are forecast to grow faster than the CN market (23.3% per year).
High Growth Earnings: 301230's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 301230's revenue (42.4% per year) is forecast to grow faster than the CN market (14% per year).
High Growth Revenue: 301230's revenue (42.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 301230's Return on Equity is forecast to be high in 3 years time